Rotavirus is an important pathogen of acute infantile gastroenteritis as well as is suspected of being one of the causative agents of benign convulsion. We evaluated the clinical and laboratory features noted in 9 young children with Rotazyme positive gastroenteritis and afebrile seizure retrospectly. Seventy-seven patients were admitted to the department of pediatrics in Yeungnam University Hospital with a history of Rotazyme positive gastroenteritis between January 1, 1991 and June 30, 1993. Afebrile convulsions have been noted in 9(11.6%) of them (7 boys and 2 girls). Their age ranged from 13 to 36 months. The seizure episodes ranged from 1 to 6 time in cluster within 2 hours. The seizure were all generalized tonic-clonic seizures lasting 1-5minutes. Serum electrolyte, EEG, brain CT and CSF findings were normal except a mild pleocytosis in one patient. Any type of epilepsy was not occurred and psychomotor development was normal in 7 patients who were followed up for 6-44 months Afebrile convulsions are sometimes found in patients with rotavirus gastroenteritis. They are characterized by brief generalized seizure or seizures in cluster, normal laboratory findings and good prognosis. We believe that individualized approach is needed in the management of rotavirus gastroenteritis with afebrile convulsion.
Brain ; Child ; Electroencephalography ; Epilepsy ; Gastroenteritis* ; Humans ; Leukocytosis ; Pediatrics ; Prognosis ; Rotavirus ; Seizures*

No abstract available.
Fallopian Tubes* ; Female

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse reactions to drugs, which carry significant morbidities and mortalities. Although SJS and TEN can be treated by corticosteroids or intravenous immunoglobulin, they may be induced by steroids. We experienced a 36-year-old man who developed whole body erythromatous maculopapular rashes and multiple bullae after ingestion of deflazacort. After avoidance of deflazacort and use of dexamethasone, skin lesions resorbed. We reported a case of TEN diagnosed by characteristic clinical findings with a brief review of the literature.
Adrenal Cortex Hormones ; Adult ; Dexamethasone ; Drug Hypersensitivity Syndrome ; Eating ; Exanthema ; Humans ; Immunoglobulins ; Mortality ; Nephrotic Syndrome ; Skin ; Steroids ; Stevens-Johnson Syndrome*

Crohn’s disease (CD) is a relapsing and progressive condition characterized by diarrhea, abdominal pain, weight loss, and hematochezia that results in serious complications such as perforations, fistulas, and abscesses. Various medications, interventions, and surgical treatments have been used to treat CD. The Korean guidelines for CD management were distributed in 2012 and revised in 2017 by the Inflammatory Bowel Disease (IBD) Research Group of the Korean Association for the Study of Intestinal Diseases. Substantial progress in mucosal immunologic research has elucidated the pathophysiology of IBD, leading to development of biological agents for treatment of CD. The first developed biologic agent, tumor necrosis factor-α agents, were shown to be efficacious in CD, heralding a new era in management of CD. Subsequently, vedolizumab, a monoclonal antibody against integrin α4β7, and ustekinumab, a human monoclonal antibody that inhibits the common p40 subunit of interleukin-12 and interleukin-23, were both approved for clinical use and are efficacious and safe for both induction and maintenance of remission in moderate-to-severe CD patients. Moreover, a recent study showed the non-inferiority of CT-P13, an infliximab biosimilar, compared with infliximab in CD patients. The third Korean guidelines for CD management provide updated information regarding treatment of moderate-to-severe CD patients with biologic agents.